Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
Background. Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. This study aimed to determine the types, grades, and time course of cytopenia in CML patien...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/7696204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566333259120640 |
|---|---|
| author | Angela McLigeyo Jamilla Rajab Mohammed Ezzi Peter Oyiro Yatich Bett Andrew Odhiambo Matilda Ong’ondi Sitna Mwanzi Mercy Gatua NAOthieno- Abinya |
| author_facet | Angela McLigeyo Jamilla Rajab Mohammed Ezzi Peter Oyiro Yatich Bett Andrew Odhiambo Matilda Ong’ondi Sitna Mwanzi Mercy Gatua NAOthieno- Abinya |
| author_sort | Angela McLigeyo |
| collection | DOAJ |
| description | Background. Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. This study aimed to determine the types, grades, and time course of cytopenia in CML patients on imatinib at a Nairobi hospital. Methods. This was a cross-sectional descriptive study of adult patients aged ≥18 years followed up at the Glivec International Patient Access Program (GIPAP) clinic from 2007 to 2015. Patients who developed cytopenia within 12 months of initiating imatinib were eligible. Clinical and hematologic data were retrieved from the patients’ charts and entered into a study proforma. Measures of central tendency such as mean, median, mode, standard deviation, and variance were used for analysis. Results. Sixty three percent (63.6%) of the 94 patients developed a monocytopenia, with anemia seen in 34%, neutropenia in 27.6%, and thrombocytopenia in 8% of the 94 patients. Anemia plus neutropenia was the most common bicytopenia at 12.7%. Pancytopenia was seen in only 5 of the 94 patients. Most of the cytopenia was grades 2 and 3. Anemia was present at baseline while neutropenia and thrombocytopenia developed within 12 months of imatinib initiation. Anemia resolved during the first 12 months of therapy while neutropenia and thrombocytopenia resolved within 24–36 months of treatment. Conclusion. Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24–36 months after imatinib initiation. |
| format | Article |
| id | doaj-art-40d509a1e6fe456c9454bd7faf7930d8 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-40d509a1e6fe456c9454bd7faf7930d82025-02-03T01:04:19ZengWileyAdvances in Hematology1687-91041687-91122020-01-01202010.1155/2020/76962047696204Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time CourseAngela McLigeyo0Jamilla Rajab1Mohammed Ezzi2Peter Oyiro3Yatich Bett4Andrew Odhiambo5Matilda Ong’ondi6Sitna Mwanzi7Mercy Gatua8NAOthieno- Abinya9Department of Medicine, Maseno University, Kisumu, KenyaDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, KenyaDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, KenyaHemato–Oncology Unit, Kenyatta National Hospital, Nairobi, KenyaMoi Teaching and Referral Hospital, Eldoret, KenyaDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, KenyaHemato–Oncology Unit, Kenyatta National Hospital, Nairobi, KenyaAga Khan University Teaching Hospital, Nairobi, KenyaDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, KenyaDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, KenyaBackground. Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. This study aimed to determine the types, grades, and time course of cytopenia in CML patients on imatinib at a Nairobi hospital. Methods. This was a cross-sectional descriptive study of adult patients aged ≥18 years followed up at the Glivec International Patient Access Program (GIPAP) clinic from 2007 to 2015. Patients who developed cytopenia within 12 months of initiating imatinib were eligible. Clinical and hematologic data were retrieved from the patients’ charts and entered into a study proforma. Measures of central tendency such as mean, median, mode, standard deviation, and variance were used for analysis. Results. Sixty three percent (63.6%) of the 94 patients developed a monocytopenia, with anemia seen in 34%, neutropenia in 27.6%, and thrombocytopenia in 8% of the 94 patients. Anemia plus neutropenia was the most common bicytopenia at 12.7%. Pancytopenia was seen in only 5 of the 94 patients. Most of the cytopenia was grades 2 and 3. Anemia was present at baseline while neutropenia and thrombocytopenia developed within 12 months of imatinib initiation. Anemia resolved during the first 12 months of therapy while neutropenia and thrombocytopenia resolved within 24–36 months of treatment. Conclusion. Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24–36 months after imatinib initiation.http://dx.doi.org/10.1155/2020/7696204 |
| spellingShingle | Angela McLigeyo Jamilla Rajab Mohammed Ezzi Peter Oyiro Yatich Bett Andrew Odhiambo Matilda Ong’ondi Sitna Mwanzi Mercy Gatua NAOthieno- Abinya Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course Advances in Hematology |
| title | Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course |
| title_full | Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course |
| title_fullStr | Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course |
| title_full_unstemmed | Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course |
| title_short | Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course |
| title_sort | cytopenia among cml patients on imatinib in kenya types grades and time course |
| url | http://dx.doi.org/10.1155/2020/7696204 |
| work_keys_str_mv | AT angelamcligeyo cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT jamillarajab cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT mohammedezzi cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT peteroyiro cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT yatichbett cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT andrewodhiambo cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT matildaongondi cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT sitnamwanzi cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT mercygatua cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse AT naothienoabinya cytopeniaamongcmlpatientsonimatinibinkenyatypesgradesandtimecourse |